Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, Mar 19, 08:52 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Yesterday


News

The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

MRK PFE

Pfizer’s biosimilar versions of Roche’s other cancer drugs Rituxan and Avastin (Zirabev) are also under review in the United States with FDA decisions on all expected in 2019. Pfizer and partner Merck KGaA announced that its regulatory filing in the EU looking for approval of Bavencio (avelumab), in combination with Inlyta (axitinib) for advanced renal cell carcinoma (“RCC”), was validated for review by the European Medicines Agency. EU Nod to Merck’s Keytruda Combo in Difficult Lung Cancer: Merck announced that the European Commission granted marketing approval to Keytruda, in combination with chemotherapy, as a first-line treatment for metastatic squamous non-small cell lung cancer NSCLC – a difficult-to-treat lung cancer patient population. The FDA granted the application a normal review period of 10 months and will give its decision in the fourth quarter of 2019. If approved, ubrogepant would be the first oral CGRP antibody to get approval for migraine and may be used in conjunction with other available migraine treatment.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, March 15


News

Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

MRK

Merck's Keytruda Gets EU Approval for Difficult Lung Cancer. Merck & Co., Inc. MRK announced that the European Medicines Agency (“EMA”) has approved the label expansion of its blockbuster PD-1 inhibitor, Keytruda (pembrolizumab). The drug is now approved in combination with chemotherapy (carboplatin and either paclitaxel or nab-paclitaxel) for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (“NSCLC”) — a difficult to treat lung cancer population — regardless of PD-L1 expression. This nod will help Merck gain access to a broader lung cancer patient population and boost sales of its blockbuster drug.

Read Full Details

Topics:
  • Business
  • Health

Thursday, March 14


News

Thursday’s Vital Data: Aurora Cannabis, Roku and Merck

MRK

U.S. stock futures are flirting with unchanged this morning as the market seeks to extend its gains for the fourth day in a row. Against this backdrop, futures on the Dow Jones Industrial Average are down 0.02% and S&P 500 futures are higher by 0.02%. Meanwhile, at the CBOE the single-session equity put/call volume ratio skidded to a lowly 0.52 which is just shy of a new low for 2019. At $81.60, the pharmaceutical giant ended Wednesday a pebble toss away from record territory. While MRK stock ended with a doji candle amid an otherwise lackluster trading session, its options were on fire ahead of today’s ex-dividend date.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, March 13


News

Merck (MRK) Gains But Lags Market: What You Should Know

MRK

Merck (MRK) closed at $81.60 in the latest trading session, marking a +0.46% move from the prior day. On that day, MRK is projected to report earnings of $1.06 per share, which would represent year-over-year growth of 0.95%. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.65 per share and revenue of $44.38 billion. In terms of valuation, MRK is currently trading at a Forward P/E ratio of 17.48. For comparison, its industry has an average Forward P/E of 15.19, which means MRK is trading at a premium to the group.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, March 12


News

Why Merck (MRK) is a Great Dividend Stock Right Now

MRK

Why Merck (MRK) is a Great Dividend Stock Right Now. ZacksMarch 12, 2019, 1:15 PM GMT. Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus. While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. Headquartered in Kenilworth, Merck (MRK) is a Medical stock that has seen a price change of 5.84% so far this year. The pharmaceutical company is paying out a dividend of $0.55 per share at the moment, with a dividend yield of 2.72% compared to the Large Cap Pharmaceuticals industry's yield of 2.78% and the S&P 500's yield of 1.96%.

Read Full Details

Topics:
  • Business
  • Financial
  • Entertainment

Saturday, March 09


News

Merck KGaA (MKGAF) Issues Earnings Results

MRK

Merck KGaA (OTCMKTS:MKGAF) released its quarterly earnings data on Thursday. The company reported $1.39 earnings per share for the quarter, Morningstar.com reports. Merck KGaA had a net margin of 14.94% and a return on equity of 16.90%. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 0.54.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, March 08


News

Versum, Entegris see extra merger benefits, Merck hires Goldman

MRK GS

FRANKFURT, March 8 (Reuters) - Entegris and Versum Materials on Friday highlighted additional benefits from their planned all-share merger, while rival bidder Merck KGaA said it had brought in Goldman Sachs to help with its counter offer. Electrochemicals companies Entegris and Versum said in a letter to shareholders they now expect $125 million in cost benefits, or $50 million more in annual earnings before interest, tax, depreciation and amortisation, more than originally identified. "We are confident the combined company will meet or exceed the newly stated cost synergy goals as well as realise the other benefits of this merger," Versum chairman Seifi Ghasemi and Entegris Chief Executive Bertrand Loy said in the letter. Merck on Tuesday had called on Versum's shareholders to put pressure on management to consider the German group's $5.9 billion cash bid, including debt, which the U.S. maker of chemicals for semiconductors has spurned in favour of an all-share merger with Entegris.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck KGaA mandates Goldman as additional advisor for Versum deal

MRK GS

Merck KGaA mandates Goldman as additional advisor for Versum deal. FRANKFURT (Reuters) - German drugs and lab supplies group Merck KGaA has brought in Goldman Sachs as additional advisor for its unsolicited bid for Versum Materials as it seeks to break up the U.S. company's agreed merger with a rival suitor. In an open letter on Tuesday, Merck called on Versum's shareholders to put pressure on management to consider the German group's $5.9 billion (4.5 billion pounds) cash bid, including debt, which the U.S. maker of chemicals for semiconductors has spurned in favour of an all-share merger with Entegris. Merck's takeover proposal of $48 per share in cash compares with an offer of around $39.6 worth of Entegris stock for each Versum share under the existing deal, based on Entegris' closing price of $35.38 on Wednesday.

Read Full Details

Topics:
  • Business
  • Financial
  • Science

Thursday, March 07


News

Merck KGaA says weak EM currencies to weigh on 2019 earnings

MRK

DARMSTADT, Germany (Reuters) - Germany's Merck KGaA posted a decline in adjusted fourth quarter core earnings as negative currency effects offset demand for its lab supplies and older drugs in China and the Middle East, and forecast a similar effect on 2019 earnings. Quarterly earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for special items, slipped 1.3 percent to 950 million euros ($1.07 billion), dragged lower by a weak Argentine peso. Excluding currency effects, revenue at its healthcare division rose 5.5 percent to 1.63 billion euros in the quarter, on strong demand in emerging markets for its established diabetes and blood pressure drugs and bolstered by recently launched multiple sclerosis drug Mavenclad in Europe. Revenue at its lab supplies unit surged 8.8 percent organically, also to 1.63 billion euros, boosted by demand from biotech researchers. But weak emerging market currencies canceled out those gains and family-controlled Merck said it expected a similar burden on 2019 earnings.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck KGaA says currency headwinds quell drug gains in Q4

MRK

SECTIONS. Home. Business. Markets. World. India. Technology. Money. Merck KGaA says currency headwinds quell drug gains in Q4. (Reuters) - Germany's Merck KGaA posted a 1.3 percent decline in adjusted core earnings in the fourth quarter as negative currency effects more than offset strong demand at its lab supplies division and gains from a new multiple sclerosis drug. Quarterly earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, slipped to 950 million euros ($1.07 billion), below the average analyst estimate of 981 million in a Reuters poll. ($1 = 0.8844 euros).

Read Full Details

Topics:
  • Business
  • Financial